home / stock / apre / apre news

APRE News and Press, Aprea Therapeutics Inc. From 11/05/20

Stock Information
Company Name: Aprea Therapeutics Inc.
Stock Symbol: APRE
Market: NASDAQ
Website: aprea.com
Menu
APRE APRE Quote APRE Short APRE News APRE Articles APRE Message Board
Get APRE Alerts

News, Short Squeeze, Breakout and More Instantly...
APRE - Aprea Therapeutics EPS beats by $0.16

Aprea Therapeutics (APRE): Q3 GAAP EPS of -$0.58 beats by $0.16.Ccash and cash equivalents of $101.1M.Press Release For further details see: Aprea Therapeutics EPS beats by $0.16

APRE - Aprea Therapeutics Reports Third Quarter 2020 Financial Results and Provides Update on Business Operations

BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three an...

APRE - Aprea Therapeutics to Highlight Changing Treatment Paradigm in MDS as well as Development Pipeline Progress at Virtual R&D Day Today

BOSTON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, will host a live virtual R&D Day Webinar, with pres...

APRE - Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com

BOSTON, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, today announced the launch of p53reactivation.com ....
APRE - Aprea on go with early-stage study with APR-548 in blood disorder

The FDA has signed-off Phase 1 trial of Aprea Therapeutics's (APRE) APR-548 for the treatment of TP53 mutant myelodysplastic syndromes.APR-548 is a small molecule reactivator of mutant p53 that is being developed for oral administration. For further details see: Aprea on go with ea...

APRE - Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548

BOSTON, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced that the U.S. Food and Drug Admi...

APRE - Aprea Therapeutics Appoints Michael A. Kelly to Board of Directors

BOSTON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the appointment of Michael A. K...
APRE - Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announces Governance Changes

BOSTON, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the promotion of Gregory S. Wes...

APRE - Aprea Therapeutics to Present at Upcoming Investor Conferences

BOSTON, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that  the Company is scheduled ...

APRE - Aprea Therapeutics EPS misses by $0.19

Aprea Therapeutics (NASDAQ: APRE ) : Q2 GAAP EPS of -$0.78 misses by $0.19 . More news on: Aprea Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

Previous 10 Next 10